Absci Corporation (NASDAQ: ABSI), a clinical-stage biotech company, announced a collaboration with Oracle Cloud Infrastructure and AMD to enhance its AI-driven drug discovery platform. The partnership aims to accelerate biologics design cycles and reduce costs through advanced cloud computing infrastructure.

The collaboration utilizes Oracle Cloud Infrastructure's bare metal instances powered by AMD's 5th Generation EPYC processors and ultrafast RDMA cluster networking. This setup provides Absci with low-latency networking and high throughput capabilities needed for large-scale model training and molecular-dynamics simulations.

Absci's generative AI Drug Creation Platform leverages the infrastructure to perform end-to-end antibody design and large-scale molecular-dynamics simulations. The company reports eliminating hypervisor overhead and reducing inter-GPU latency to 2.5 microseconds while achieving terabytes-per-second throughput for data streaming.

"Our mission is to push the boundaries of how we design new therapeutics," said Sean McClain, Founder and CEO of Absci. "With OCI and AMD, we are pairing our cutting-edge AI models with best-in-class infrastructure."

The partnership will incorporate AMD's next-generation Instinct MI355X GPUs to further enhance platform performance and scalability. Oracle's Dan Spellman noted that the collaboration combines bare metal GPUs, compute instances, and high-performance storage to support biologics design workflows.

Absci operates from Vancouver, Washington, with additional facilities in New York City and Switzerland. The company focuses on using generative AI to design therapeutic antibodies and other biologics, combining AI algorithms with synthetic biology validation processes.